CA2506799A1 - Modulateurs de la kinase a lignee evolutive mixte - Google Patents

Modulateurs de la kinase a lignee evolutive mixte Download PDF

Info

Publication number
CA2506799A1
CA2506799A1 CA002506799A CA2506799A CA2506799A1 CA 2506799 A1 CA2506799 A1 CA 2506799A1 CA 002506799 A CA002506799 A CA 002506799A CA 2506799 A CA2506799 A CA 2506799A CA 2506799 A1 CA2506799 A1 CA 2506799A1
Authority
CA
Canada
Prior art keywords
alkyl
dihydro
alkoxy
pyridin
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002506799A
Other languages
English (en)
Inventor
Arindam Chatterjee
Theodore Junior Goodson
Mary Margaret Mader
John Eldon Toth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2506799A1 publication Critical patent/CA2506799A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention a trait à un composé de formule (I), ou à un sel pharmaceutiquement acceptable de celui-ci comportant une quantité efficace d'un composé de formule (I) en combinaison avec un support approprié, un diluant, ou un excipient, et des procédés de traitement de troubles physiologiques, notamment l'insuffisance cardiaque globale, comprenant l'administration à un patient d'une quantité efficace d'un composé de formule (I).
CA002506799A 2002-11-21 2003-11-12 Modulateurs de la kinase a lignee evolutive mixte Abandoned CA2506799A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42832202P 2002-11-21 2002-11-21
US60/428,322 2002-11-21
PCT/US2003/035036 WO2004048383A1 (fr) 2002-11-21 2003-11-12 Modulateurs de la kinase a lignee evolutive mixte

Publications (1)

Publication Number Publication Date
CA2506799A1 true CA2506799A1 (fr) 2004-06-10

Family

ID=32393381

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002506799A Abandoned CA2506799A1 (fr) 2002-11-21 2003-11-12 Modulateurs de la kinase a lignee evolutive mixte

Country Status (5)

Country Link
EP (1) EP1567528A1 (fr)
JP (1) JP2006522735A (fr)
AU (1) AU2003298611A1 (fr)
CA (1) CA2506799A1 (fr)
WO (1) WO2004048383A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
CR9465A (es) * 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
EP1910370B1 (fr) * 2005-07-22 2015-04-22 Eli Lilly And Company Pyrrolo [1,2-b] pyrazole monohydraté porteur d'une substitution pyridin quinoline en tant qu'inhibiteur du facteur de croissance tgf-bêta
US7919519B2 (en) 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
EP1965807A4 (fr) * 2005-11-23 2010-10-27 Epix Delaware Inc Composes modulateurs du recepteur s1p et utilisation associee
JP2009530389A (ja) 2006-03-21 2009-08-27 エピックス デラウェア， インコーポレイテッド Ｓ１ｐ受容体調節化合物及びその使用
BRPI0713350B1 (pt) 2006-06-26 2022-04-12 Akebia Therapeutics Inc Composto, e, composição
MX2009010060A (es) * 2007-03-21 2010-01-20 Epix Pharm Inc Compuestos moduladores del receptor de esfingosin-1-fosfato y uso de los mismos.
ES2360929T3 (es) 2007-09-20 2011-06-10 Amgen Inc. Derivados del ácido 1-(4-(4-bencilbenzamido)-bencil)azetidin-3-carboxílico y compuestos relacionados como moduladores del receptor s1p para el tratamiento de trastornos inmunitarios.
DE102009001438A1 (de) 2009-03-10 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Carbonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102009015070A1 (de) 2009-03-30 2010-10-14 Bayer Schering Pharma Aktiengesellschaft Aminocabonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2717870B1 (fr) 2011-06-06 2017-09-27 Akebia Therapeutics Inc. Composition pour la stabilisation du facteur-2 alpha inductible par l'hypoxie utile pour le traitement du cancer
NO2686520T3 (fr) 2011-06-06 2018-03-17
SG10201910773VA (en) 2013-06-13 2020-01-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
ES2918924T3 (es) 2015-04-01 2022-07-21 Rigel Pharmaceuticals Inc Inhibidores de TGF-beta
EP3492461B1 (fr) 2016-07-29 2024-10-23 Shanghai Yingli Pharmaceutical Co. Ltd. Composé aromatique hétérocyclique azoté, son procédé de préparation, composition pharmaceutique à base de celui-ci et son application
CN110066276B (zh) 2018-01-24 2020-09-18 上海璎黎药业有限公司 芳香杂环化合物、其中间体、制备方法、药物组合物和应用
CN110066277B (zh) 2018-01-24 2021-07-23 上海璎黎药业有限公司 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
EP3790863A1 (fr) 2018-05-09 2021-03-17 Akebia Therapeutics Inc. Procédé de préparation d'acide 2-[[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino]acétique
CN114437082B (zh) * 2020-11-06 2025-04-04 江苏先声药业有限公司 喹啉类化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
EP1397364B1 (fr) * 2001-05-24 2007-07-25 Eli Lilly And Company Derives de pyrrole utilises comme agents pharmaceutiques

Also Published As

Publication number Publication date
WO2004048383A1 (fr) 2004-06-10
JP2006522735A (ja) 2006-10-05
EP1567528A1 (fr) 2005-08-31
AU2003298611A1 (en) 2004-06-18

Similar Documents

Publication Publication Date Title
CA2506799A1 (fr) Modulateurs de la kinase a lignee evolutive mixte
US9403823B2 (en) Protein kinase inhibitors
US9550772B2 (en) Azaindole derivatives as multi kinase inhibitors
CN106604997B (zh) 赖氨酸特异性脱甲基酶-1的抑制剂
US20050261331A1 (en) Substituted pyrrolopyridines
CN105722835B (zh) 3-芳基-5-取代的-异喹啉-1-酮化合物及它们的疗法应用
US7625902B2 (en) Imidazolidinone derivatives
JP4857128B2 (ja) 新規な化合物
DK2940013T3 (en) HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND
KR101126736B1 (ko) 티로신 키나아제 저해 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 포함하는 약학적 조성물
US20110112110A1 (en) Antiproliferative compounds and therapeutic uses thereof
WO2006036024A1 (fr) Inhibiteurs de pompe a protons
JP2006504755A (ja) Ｇｓｋ−３阻害薬としてのピリダジン化合物
TW201739744A (zh) 治療用化合物
US20110015185A1 (en) Benzofuran Compounds
WO2024112611A1 (fr) Modification ciblée de protéines
CN116891464A (zh) 一种at2r激动剂
CN117794898A (zh) 3-吡咯基磺酰胺化合物作为gpr17拮抗剂
NZ582934A (en) Novel heterocyclic compounds as mglu5 antagonists
CN114341135B (zh) 雌激素相关受体α(ERRα)调节剂
JP2012211085A (ja) ヘッジホッグシグナル阻害剤
TW202134213A (zh) 具有水解磷脂酸受體作動活性之化合物及其醫藥用途
CN104520304B (zh) 咪唑并[2，1‑b]噻唑衍生物、其制备及作为药物的用途
US7511065B2 (en) Mixed lineage kinase modulators
CN119677717A (zh) 用于治疗trpm3介导的病症的吲哚嗪衍生物

Legal Events

Date Code Title Description
FZDE Dead